Preclinical studies with adrenomedullin and its binding protein as cardiovascular protective agents for hemorrhagic shock.
Traumatic injury is a major, largely unrecognized public health problem in the US that cuts across race, gender, age, and economic boundaries. The resulting loss of productive life years exceeds that of any other disease, with societal costs of $469 billion annually. Most trauma deaths result either from insufficient tissue perfusion due to excessive blood loss, or the development of inflammation, infection, and vital organ damage following resuscitation. Clinical management of hemorrhagic shock relies on massive and rapid infusion of fluids to maintain blood pressure. However, the majority of victims with severe blood loss do not respond well to fluid restoration. The development of effective strategies for resuscitation of traumatic blood loss is therefore critically needed. We have recently discovered that the vascular responsiveness to a recently-discovered potent vasodilatory peptide, adrenomedullin (AM) is depressed after severe blood loss, which may be due to downregulation of a novel specific binding protein, AM binding protein-1 (AMBP-1). Using three different animal models of hemorrhage (controlled hemorrhage with large volume resuscitation, controlled hemorrhage with low volume resuscitation, and uncontrolled hemorrhage with minimum resuscitation), we have shown that cell and organ injury occurs after hemorrhage despite fluid resuscitation. Administration of AM/AMBP-1 significantly improves cardiac output, heart performance and tissue perfusion, attenuates hepatic and renal injury, decreases pro-inflammatory cytokines, prevents metabolic acidosis, and reduces hemorrhage-induced mortality. Thus, administration of AM/AMBP-1 appears to be a novel and useful approach for restoring cardiovascular responses, preventing organ injury, and reducing mortality after hemorrhagic shock.
Wu
Rongqian
R
Department of Surgery, North Shore University Hospital and Long Island Jewish Medical Center, Manhasset, NY, USA.
Wang
Ping
P
D053607:Adrenomedullin / Q000494:pharmacology*; D000818:Animals; D017242:Complement Factor H / Q000494:pharmacology*; D006801:Humans; D020011:Protective Agents / Q000494:pharmacology*; D012151:Resuscitation; D012771:Shock, Hemorrhagic / Q000188:drug therapy*
D053607:Adrenomedullin; D017242:Complement Factor H; D020011:Protective Agents; C493495:CFH protein, human